Clinical Trial Update: Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on pemigatinib plus an immune checkpoint inhibitor for FGFR1/2/3-altered advanced solid tumors; the study is not yet recruiting. T…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Gastric Cancer
• Lung Cancer
• Soft Tissue Sarcoma
• Urothelial Carcinoma

Drugs mentioned

• Immune checkpoint inhibitor (unspecified)
• Pemigatinib (pemigatinib)

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: Urothelial Carcinoma, Breast Neoplasms | Phase 2 | Status: NOT_YET_RECRUITING